Cerebrolysin • SS-31 • BDNF • Semax • Dihexa • Thymosin Beta-4 • BPC-157
A stroke can happen within minutes. Brain recovery can continue for months or even years.
After the initial injury, the brain can undergo a remarkable process of adaptation called neuroplasticity. Surviving neurons can reorganize, synaptic connections can change, blood vessels can remodel and neural networks can gradually adapt to compensate for damaged areas.
This has created an exciting area of research:
Could specific peptides and neurotrophic factors support the brain’s natural recovery after stroke?
Researchers are investigating compounds including Cerebrolysin, SS-31, BDNF, Semax, Dihexa, Thymosin Beta-4 and BPC-157 for their potential roles in neuronal survival, mitochondrial function, neuroplasticity, synaptic remodeling, angiogenesis and brain repair.
The evidence varies considerably. Some have been studied in humans, while others remain predominantly experimental.
What Happens to the Brain After a Stroke?
Following an ischemic stroke, reduced blood flow deprives brain tissue of oxygen and nutrients.
This can trigger:
Ischemia → excitotoxicity → mitochondrial dysfunction → oxidative stress → inflammation → neuronal injury
But the brain’s response doesn’t stop with the initial injury.
During recovery, several processes can contribute to neurological improvement:
- Neuroplasticity
- Synaptic remodeling
- Axonal sprouting
- Angiogenesis
- Neurogenesis
- Oligodendrogenesis
- Neurovascular remodeling
- Mitochondrial recovery
This is the biological foundation underlying much of modern stroke rehabilitation.
The emerging question is whether specific biological signals can support these processes.
Why Are Peptides Interesting for Stroke Recovery?
Peptides can act as powerful biological messengers.
Depending on the molecule, researchers are exploring effects on:
Neuronal survival
Mitochondrial function
Growth-factor signaling
Synaptic plasticity
Blood-vessel formation
Inflammation
Neural regeneration
Cellular repair
Rather than thinking about a single “stroke peptide,” it is more useful to consider different compounds according to the biological pathway they may influence.
1. Cerebrolysin: Neurotrophic Support and Brain Recovery
Cerebrolysin is a preparation containing low-molecular-weight peptides and amino acids derived from porcine brain tissue.
It is among the more extensively studied peptide-based approaches in stroke research, with investigations into neurotrophic signaling, neuronal survival and neuroplasticity.
What does the research show?
A 2017 meta-analysis of nine randomized controlled trials involving 1,879 patients reported improvement in early neurological recovery measured by NIHSS. A 2025 meta-analysis involving 14 randomized trials and 2,884 patients also reported improvement in NIHSS change, although functional independence did not reach statistical significance.
Cerebrolysin therefore has a substantially larger clinical research base in stroke than many of the newer experimental peptides.
2. SS-31: Protecting the Neuron’s Energy Machinery
SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide.
This makes it particularly interesting in neurological research.
The brain consumes enormous amounts of energy, and neurons are highly dependent on healthy mitochondria for ATP production and cellular survival.
SS-31 targets cardiolipin, an important component of the inner mitochondrial membrane.
Researchers are investigating whether this can:
- Improve mitochondrial function
- Reduce oxidative stress
- Protect neuronal cells
- Support cellular energy production
- Reduce mitochondrial-related inflammation
What does the research show?
A recent experimental stroke study found that SS-31 preserved cardiolipin, reduced neuronal ferroptosis and improved mitochondrial homeostasis following cerebral ischemia/reperfusion injury. Another experimental study combining SS-31 with NMN reported reduced neurological deficits and brain injury in mice. (pubmed.ncbi.nlm.nih.gov)
Research in aged mice has also reported improved cerebrovascular function, neurovascular coupling, memory and motor learning following SS-31 administration. (pubmed.ncbi.nlm.nih.gov)
This makes SS-31 particularly interesting for the emerging concept of mitochondrial support for brain recovery.
3. BDNF: One of the Brain’s Key Neuroplasticity Signals
BDNF — brain-derived neurotrophic factor — is not simply another peptide supplement. It is an endogenous neurotrophin produced naturally in the nervous system.
BDNF plays an important role in:
- Neuronal survival
- Synaptic plasticity
- Learning and memory
- Dendritic growth
- Synaptic strengthening
- Motor learning
This makes BDNF highly relevant to stroke rehabilitation.
After a stroke, successful recovery requires surviving neural networks to reorganize and establish more effective patterns of communication.
BDNF is one of the molecules involved in this process.
What does the research show?
Experimental stroke research has demonstrated that BDNF signaling can influence neuronal survival, synaptic remodeling and functional recovery. Human research also suggests that circulating BDNF levels are associated with neurological recovery after stroke, although blood BDNF does not necessarily reflect brain BDNF activity directly.
The major research challenge is how to safely and effectively manipulate BDNF signaling in the human brain.
4. Semax: The BDNF–Neuroplasticity Connection
Semax is a synthetic peptide derived from an ACTH-related sequence and has been investigated extensively in Russian and Eastern European neurological research.
Its potential relationship with BDNF and neuroplasticity is particularly interesting.
What does the research show?
A clinical study involving 110 patients following ischemic stroke reported increased plasma BDNF following Semax administration, alongside improvements in measures including the Barthel Index and motor performance. (pubmed.ncbi.nlm.nih.gov)
The findings have contributed to interest in Semax as a potential modulator of neurotrophic signaling during neurological recovery.
5. Dihexa: Exploring New Neural Connections
Dihexa is an experimental compound that has attracted interest because of research into synaptogenesis — the formation of connections between neurons.
It has been investigated in relation to the HGF/c-Met signaling pathway, which is involved in neuronal growth, survival and synaptic development.
Why is this interesting after stroke?
Because recovering function isn’t simply about keeping neurons alive.
The surviving brain also needs to reorganize communication between neural networks.
What does the research show?
Preclinical studies involving Dihexa and HGF/c-Met signaling have reported effects associated with synaptic formation and cognitive function. Direct clinical evidence demonstrating improved recovery after stroke in humans is currently lacking.
Dihexa therefore remains an experimental neuroplasticity candidate.
- Thymosin Beta-4: Neuroregeneration and Tissue Remodeling
Thymosin Beta-4 has been extensively investigated in regenerative biology.
Research has explored potential effects on:
- Angiogenesis
- Neurogenesis
- Axonal growth
- Cell migration
- Oligodendrogenesis
- Tissue remodeling
These mechanisms are relevant to the recovering brain because restoration involves both vascular and neural remodeling.
What does the research show?
Experimental stroke research has reported improved neurological outcomes with Thymosin Beta-4 and proposed effects involving angiogenesis, neurogenesis, axonal remodeling and oligodendrogenesis. (pubmed.ncbi.nlm.nih.gov)
Most stroke-specific evidence remains preclinical.
7. BPC-157: Experimental Research in Brain Injury
BPC-157 is another peptide that has generated interest in regenerative medicine.
Experimental research has investigated its potential effects on:
Vascular function
Nitric oxide signaling
Inflammation
Angiogenesis
Cell survival
What does the research show?
Animal studies involving cerebral ischemia and reperfusion have reported reductions in neurological injury and improvements in behavioral outcomes following BPC-157 administration, with research exploring pathways including Akt, VEGFR2, NOS and NF-κB.
These findings are scientifically interesting, but clinical evidence for post-stroke recovery in humans remains limited.
How Could These Peptides Fit Into Brain Recovery?
One useful way to understand the research is to look at the different biological targets.
Cerebrolysin
Neurotrophic support
SS-31
Mitochondrial function and cellular energy
BDNF
Synaptic plasticity and neuronal adaptation
Semax
BDNF-related neuroplasticity
Dihexa
Synaptogenesis and neural connectivity
Thymosin Beta-4
Angiogenesis and regenerative remodeling
BPC-157
Vascular and tissue-repair pathways
These mechanisms are different, but they intersect around a common objective:
Supporting the brain’s ability to adapt after injury.
Neuroplasticity: The Heart of Brain Recovery
Neuroplasticity is perhaps the most important concept connecting much of this research.
After stroke, the brain can:
Strengthen surviving connections
Create new connections
Recruit alternative neural pathways
Reorganize functional networks
Adapt through repeated learning
This is why rehabilitation is so important.
Physiotherapy, occupational therapy, speech therapy, cognitive training, balance exercises and other rehabilitation approaches provide repeated stimulation that can reinforce useful neural pathways.
The exciting research question is whether biological signals can potentially support the environment in which this plasticity occurs.
Peptides and Neurorehabilitation
Think of recovery as two interacting components:
Biological potential
The brain needs viable neurons, functioning mitochondria, growth factors and the ability to remodel synapses.
Functional stimulation
The brain needs repeated movement, learning and sensory input to reinforce useful pathways.
This creates an emerging research concept:
Biological signaling + targeted rehabilitation = enhanced opportunity for neuroplasticity
This does not mean that peptides replace physiotherapy or neurological rehabilitation.
Rather, researchers are investigating whether certain biological pathways could complement rehabilitation.
Does the Stage After Stroke Matter?
The biology of the brain changes throughout recovery.
In the early period, research focuses heavily on:
Neuronal survival
Excitotoxicity
Oxidative stress
Mitochondrial dysfunction
Inflammation
As recovery progresses, processes such as:
Angiogenesis
Neurogenesis
Axonal sprouting
Synaptic remodeling
Neuroplasticity
become increasingly relevant.
This suggests that timing and biological context may be important when studying peptide-based approaches to brain recovery.
Which Peptides Are Being Studied for Brain Recovery After Stroke?
Cerebrolysin — neurotrophic signaling and neurological recovery
SS-31 — mitochondrial protection and cellular energy
BDNF — synaptic plasticity and neuronal adaptation
Semax — BDNF-related neuroplasticity
Dihexa — synaptic connectivity
Thymosin Beta-4 — angiogenesis and regenerative remodeling
BPC-157 — vascular and experimental tissue-repair pathways
The evidence is not equivalent across these compounds. Some have human research, while others remain largely preclinical.
The Future of Peptides for Stroke Recovery
The future of brain recovery may not revolve around one “miracle peptide.”
The brain is a highly interconnected biological system involving:
Neurons + mitochondria + blood vessels + glial cells + immune signaling + growth factors + synapses
This is why the most interesting research may ultimately involve targeting multiple aspects of the recovery environment.
One compound may support mitochondrial function.
Another may influence neurotrophic signaling.
Another may affect synaptic remodeling.
Another may influence vascular regeneration.
The challenge is understanding how these pathways interact — and determining which interventions are safe and effective in humans.
The Takeaway
The question “Which peptides can help after a stroke?” is opening an exciting area of research in regenerative neuroscience.
Cerebrolysin has one of the larger clinical research bases among peptide-based neurological interventions.
SS-31 brings mitochondrial protection and cellular energy into the conversation.
BDNF is central to the biology of synaptic plasticity and neural adaptation.
Semax has generated interest through its relationship with BDNF.
Dihexa is being investigated for synaptic connectivity.
Thymosin Beta-4 has attracted attention for neurovascular and regenerative mechanisms.
BPC-157 remains an experimental compound with interesting preclinical findings.
Together, these approaches point toward a fascinating possibility:
The future of stroke recovery may involve not only protecting the brain, but helping the surviving brain reorganize, reconnect and function more effectively.
That is where peptide research, mitochondrial biology, neuroplasticity and advanced neurorehabilitation converge.
Frequently Asked Questions
1. Which peptides are being studied after stroke?
Research has investigated Cerebrolysin, SS-31, BDNF, Semax, Dihexa, Thymosin Beta-4 and BPC-157 in different aspects of neurological recovery and brain repair.
2. Which peptide is best for stroke recovery?
There is currently no scientific basis for declaring one peptide universally “best.” The compounds have different mechanisms and substantially different levels of clinical evidence.
3. Can SS-31 help the brain after a stroke?
SS-31 is being investigated for its ability to protect mitochondria and reduce mitochondrial oxidative stress. Experimental stroke studies have reported neuroprotective effects, but clinical evidence demonstrating improved post-stroke recovery in humans is not yet established.
4. Can BDNF help after stroke?
BDNF is an important neurotrophic factor involved in synaptic plasticity, neuronal survival and learning. It is therefore highly relevant to the biology of stroke recovery, although translating BDNF-based approaches into effective clinical therapies remains an active research area.
5. Is Dihexa being studied for stroke recovery?
Dihexa is primarily an experimental compound investigated for synaptic formation and neural connectivity. Direct human evidence for post-stroke recovery is currently lacking.
6. Can peptides replace stroke rehabilitation?
No. Peptide research does not replace neurological care or rehabilitation. Stroke recovery requires appropriate medical management and individualized rehabilitation.